Skip to content
Homepage
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Posted Date:
March 4, 2026
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Zhongshan Kangfang Biological Medicine Co., LTD
March 4, 2026
Akeso’s IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
Zhongshan Kangfang Biological Medicine Co., LTD
February 11, 2026
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
Zhongshan Kangfang Biological Medicine Co., LTD
February 8, 2026
Ivonescimab Included in FirstWord Pharma’s “The Drugs That Will Shape 2026”
Zhongshan Kangfang Biological Medicine Co., LTD
January 29, 2026
Prev
1
2
